Loading
Every triple-negative patient under 60 in the UK should be offered a BRCA test at diagnosis because the result now changes treatment, and many should be offered a trial, but no one publishes how many are. A national audit through existing cancer registration and genomic laboratory data would show the gap by region before anyone tries to close it.
Placeholder for the UK-specific gaps named on the UK and NHS page for triple-negative breast cancer. What exists now: the OlympiA six-year update makes germline status a treatment decision with a survival benefit (hazard ratio 0.72); Atchley's series shows a triple-negative diagnosis itself predicts a BRCA1 variant in 57 percent of carriers; the ASCO, ASTRO and SSO guideline and NICE criteria both support testing at diagnosis; the POSH cohort shows the UK can assemble national young-onset breast cancer data with ethnicity and outcome. What is missing is a published figure for the proportion of eligible triple-negative patients tested within the neoadjuvant window, when the result can change surgery and adjuvant therapy, and for the proportion offered a trial, by region and ethnicity.
Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.
Sets the surgical and systemic rules for the roughly one in five triple-negative patients who carry a germline BRCA variant; the adjuvant gap it named was filled by OlympiA the following year.
The UK's own evidence that the disparity is not only American and not only about access: within the NHS, with equal chemotherapy use, young Black women had more triple-negative disease and worse survival. It anchors the disparities idea on the triple-negative page and the UK and NHS page.
Turned the laboratory link between BRCA1 and basal-like biology into a clinical rule: a triple-negative diagnosis is itself a reason to offer germline testing, now embedded in NICE, NCCN and ESMO criteria.
Shares Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Fragmented care and guideline gaps, Data silos and the tag tnbc-evidence.
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, OlympiA, Olaparib, BRCA1 / BRCA2 (HRD) and the tag tnbc-evidence.
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Close the gap between who gets triple-negative breast cancer and who is in its trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.